Although Cetuximab is highly effective in the metastatic
setting, the preliminary results of the NCCTG Intergroup
0147 study evaluating its use in the adjuvant setting
for kras mutated and wild-type tumors - indicates
that it neither improves disease free survival nor overall
survival